Evidence map›Paper›PMID 12507915›Full record

ArticleThe American journal of pathology2003

Tissue-specific inactivation of murine M6P/IGF2R.

Andrew A Wylie, David J Pulford, Alison J McVie-Wylie, Robert A Waterland, Heather K Evans, Yuan-Tsong Chen, Catherine M Nolan, Terry C Orton, Randy L Jirtle

Open access · bronzeAbstract read
In one paragraph

Article in The American journal of pathology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 66 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Renin Activity in Heart Failure with Reduced Systolic Function-New Insights.International journal of molecular sciences · 2019
    Review
  9. Article
  10. Article
  11. Article
  12. Functional evolution of IGF2:IGF2R domain 11 binding generates novel structural interactions and a specific IGF2 antagonist.Proceedings of the National Academy of Sciences of the United States of America · 2016
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Adjunctive β2-agonist treatment reduces glycogen independently of receptor-mediated acid α-glucosidase uptake in the limb muscles of mice with Pompe disease.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2014
    Article
  18. Adjunctive β2-agonists reverse neuromuscular involvement in murine Pompe disease.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2013
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 4 countries.

Andrew A WylieDepartment of Radiation Oncology, Duke University Medical Center, Durham, North Carolina 27710, USA.
David J Pulford
Alison J McVie-Wylie
Robert A Waterland
Heather K Evans
Yuan-Tsong Chen
Catherine M Nolan
Terry C Orton
Randy L Jirtle
Medical Genetics Center · DEDuke University · USAstraZeneca (United Kingdom) · GBDuke Medical Center · USUniversity College Dublin · IE

Funding

TUMOR SUPPRESSOR FUNCTION OF THE M6P/IGF2 RECEPTORR01ES008823 · NIEHS · DUKE UNIVERSITY · PI JIRTLE, RANDY L · 1997 to 2007
$2.2M
SURVIVAL AND CARCINOGENESIS IN TRANSPLANTED HEPATOCYTESR01CA025951 · NCI · DUKE UNIVERSITY · PI JIRTLE, RANDY L · 1985 to 2004
$1.4M
NCI NIH HHS CA25951NCI NIH HHS R01 CA025951NIEHS NIH HHS ES08823NIEHS NIH HHS R01 ES008823
6 · The paper itself

Abstract

The mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R) encodes a multifunctional protein involved in lysosomal enzyme trafficking, fetal organogenesis, tumor suppression, and T cell- mediated immunity. M6P/IGF2R is an imprinted gene in mice with expression only from the maternal allele. Complete knockout of this gene causes neonatal lethality, thus preventing analysis of its multifunctional role postnatally. To help elucidate the biological functions of M6P/IGF2R in adulthood, we generated both complete and tissue-specific M6P/IGF2R knockout mice using the Cre/loxP system. We confirm that complete M6P/IGF2R knockout results in fetal overgrowth and neonatal lethality. In contrast, tissue-specific inactivation of this gene in either the liver or skeletal and cardiac muscle gives rise to viable animals with no obvious phenotype. The successful creation of viable tissue-specific M6P/IGF2R knockout mouse models will now allow for detailed analysis of receptor function in a number of cellular processes including brain development, carcinogenesis, lysosomal trafficking, and T cell-mediated immunity.

Indexed as

Disease Models, AnimalAbnormalities, MultipleAllelesAnimalsAnimals, NewbornFemaleFetal ViabilityGenes, LethalGene TargetingGenomic ImprintingHeterozygoteHypertrophyIntegrasesKidneyLiverLungCre recombinaseIntegrasesReceptor, IGF Type 2Viral Proteins

Identifiers

PMID12507915
PMCPMC1851115
OpenAlexW2025024828

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.